BNP Paribas Financial Markets Cuts Position in Insulet Corporation $PODD

BNP Paribas Financial Markets reduced its position in Insulet Corporation (NASDAQ:PODD) by 38.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 74,466 shares of the medical instruments supplier’s stock after selling 46,233 shares during the period. BNP Paribas Financial Markets’ holdings in Insulet were worth $21,166,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Forsta AP Fonden boosted its position in Insulet by 53.6% during the fourth quarter. Forsta AP Fonden now owns 46,220 shares of the medical instruments supplier’s stock valued at $13,138,000 after purchasing an additional 16,120 shares in the last quarter. Norges Bank purchased a new position in Insulet in the 4th quarter worth approximately $300,794,000. Eurizon SLJ Capital Ltd purchased a new position in Insulet during the fourth quarter worth about $349,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Insulet during the fourth quarter worth about $7,741,000. Finally, Fideuram Asset Management Ireland dac purchased a new stake in shares of Insulet during the fourth quarter worth approximately $41,000.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Canaccord Genuity Group reduced their price objective on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Sanford C. Bernstein dropped their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Truist Financial reduced their price target on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, William Blair began coverage on shares of Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Twenty-one research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $252.04.

Insulet Stock Up 4.7%

PODD opened at $153.22 on Friday. The firm’s 50-day simple moving average is $175.73 and its 200-day simple moving average is $238.90. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The firm has a market cap of $10.61 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.15 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.36% of the stock is currently owned by company insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.